Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

$24.99

Analysis of Liquidity Ratios

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Liquidity Ratios (Summary)

Regeneron Pharmaceuticals Inc., liquidity ratios

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Current ratio
Quick ratio
Cash ratio

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The liquidity position, as indicated by the current, quick, and cash ratios, demonstrates a generally strengthening trend from 2021 through 2023, followed by a moderation in subsequent years. All three ratios exhibit increases initially, suggesting improved short-term solvency, before declining from 2023 to 2025.

Current Ratio
The current ratio increased notably from 3.56 in 2021 to 5.69 in 2023, indicating a growing ability to cover short-term liabilities with short-term assets. A subsequent decrease to 4.13 by 2025 suggests a lessening of this advantage, though the ratio remains above the initial 2021 level. This indicates a potential shift in the composition of current assets or current liabilities.
Quick Ratio
Similar to the current ratio, the quick ratio shows improvement from 2.98 in 2021 to 4.82 in 2023. This suggests an increasing capacity to meet short-term obligations with the most liquid assets. The decline to 3.28 in 2025, while present, still represents a value higher than that observed in 2021. The quick ratio’s trend mirrors the current ratio, suggesting changes in both cash and near-cash assets, as well as current liabilities.
Cash Ratio
The cash ratio experienced the most substantial relative increase, moving from 1.45 in 2021 to 3.17 in 2023. This indicates a significant rise in the proportion of current assets held as cash. The ratio then decreased to 1.97 by 2025, though it remains considerably higher than the 2021 value. This suggests a potential strategic deployment of cash reserves in later periods.

Overall, the observed trends suggest a period of liquidity enhancement followed by a stabilization and slight moderation. The consistent declines from 2023 to 2025 across all three ratios warrant further investigation to determine the underlying causes and potential implications for the company’s financial flexibility.


Current Ratio

Regeneron Pharmaceuticals Inc., current ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in thousands)
Current assets
Current liabilities
Liquidity Ratio
Current ratio1
Benchmarks
Current Ratio, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Current Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Current Ratio, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The current ratio exhibited a generally positive trend from 2021 to 2023, followed by a decline in the subsequent two years. This indicates fluctuating, but generally healthy, short-term liquidity over the analyzed period.

Current Ratio Trend
The current ratio increased from 3.56 in 2021 to 5.69 in 2023, demonstrating a strengthening ability to cover short-term obligations with short-term assets. This substantial improvement suggests enhanced liquidity management or a favorable shift in the composition of current assets and liabilities.
However, beginning in 2023, the current ratio began to decrease, falling to 4.73 in 2024 and further to 4.13 in 2025. While remaining above the value observed in 2021, this downward trend warrants attention. It suggests a potential weakening in the company’s short-term liquidity position, possibly due to an increase in current liabilities or a decrease in current assets.
Underlying Components
Current assets increased from US$14,014,900 thousand in 2021 to US$19,479,200 thousand in 2023, contributing to the initial rise in the current ratio. A subsequent decrease to US$18,021,900 thousand in 2025 partially explains the ratio’s decline.
Current liabilities decreased from US$3,932,500 thousand in 2021 to US$3,141,300 thousand in 2022, further bolstering the current ratio. However, current liabilities have been increasing since 2022, reaching US$4,368,400 thousand in 2025, which has contributed to the observed downward trend in the current ratio.

The observed fluctuations in the current ratio suggest a dynamic relationship between current assets and current liabilities. Continued monitoring of these components is recommended to understand the drivers behind these changes and assess any potential risks to short-term financial health.


Quick Ratio

Regeneron Pharmaceuticals Inc., quick ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in thousands)
Cash and cash equivalents
Marketable securities
Accounts receivable, net
Total quick assets
 
Current liabilities
Liquidity Ratio
Quick ratio1
Benchmarks
Quick Ratio, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Quick Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Quick Ratio, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The quick ratio exhibited a fluctuating pattern over the five-year period. Initially, the ratio increased significantly before declining in later years. A review of the underlying components reveals the drivers of these changes.

Overall Trend
The quick ratio demonstrated an initial increase from 2.98 in 2021 to a peak of 4.82 in 2023. Subsequently, the ratio decreased to 3.28 by 2025, indicating a weakening, though still healthy, short-term liquidity position.
Quick Asset Evolution
Total quick assets increased from US$11,731,200 thousand in 2021 to US$16,512,100 thousand in 2023, representing substantial growth in readily convertible assets. However, quick assets then experienced a decline, reaching US$14,346,300 thousand in 2025. This suggests a potential shift in asset allocation or utilization.
Current Liability Dynamics
Current liabilities decreased from US$3,932,500 thousand in 2021 to US$3,141,300 thousand in 2022. They then increased to US$4,368,400 thousand by 2025. This increase in current liabilities, coupled with the decline in quick assets in the latter period, contributed to the observed decrease in the quick ratio.
Ratio Interplay
The substantial increase in the quick ratio between 2021 and 2023 was primarily driven by the faster growth of quick assets relative to current liabilities. The subsequent decline in the ratio from 2023 to 2025 reflects a combination of decreasing quick assets and increasing current liabilities. Despite the decline, the quick ratio remained above 3.0 throughout the period, suggesting a generally strong ability to meet short-term obligations with its most liquid assets.

The observed fluctuations warrant further investigation into the specific factors influencing both quick asset levels and current liability balances to understand the underlying business decisions and their impact on short-term financial health.


Cash Ratio

Regeneron Pharmaceuticals Inc., cash ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in thousands)
Cash and cash equivalents
Marketable securities
Total cash assets
 
Current liabilities
Liquidity Ratio
Cash ratio1
Benchmarks
Cash Ratio, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Cash Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Cash Ratio, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The cash ratio exhibited a generally increasing trend from 2021 to 2023, followed by a decline in the subsequent two years. This indicates fluctuating, but generally strong, short-term liquidity over the analyzed period.

Cash Ratio Trend
In 2021, the cash ratio stood at 1.45. A substantial increase was observed in 2022, reaching 2.46, suggesting a significant improvement in the company’s ability to meet its current obligations with only cash and cash equivalents. This positive trend continued into 2023, with the ratio peaking at 3.17, representing the strongest liquidity position within the observed timeframe. However, a decrease to 2.28 occurred in 2024, and a further decline to 1.97 was recorded in 2025. Despite these decreases, the ratio remained above the 2021 level throughout the entire period.

Total cash assets increased significantly from 2021 to 2023, mirroring the rise in the cash ratio. The peak in cash assets in 2023 (US$10,844,800 in thousands) likely contributed to the highest cash ratio observed that year. A subsequent decrease in total cash assets in 2024 and 2025 coincided with the declining cash ratio.

Current Liabilities
Current liabilities decreased from 2021 to 2022, potentially contributing to the initial increase in the cash ratio. However, current liabilities then increased in 2023 and 2024, and continued to rise in 2025. This upward trend in current liabilities likely exerted downward pressure on the cash ratio in the later years of the period.

The interplay between increasing current liabilities and decreasing cash assets from 2023 to 2025 explains the observed decline in the cash ratio. While the company maintained a cash ratio above 1.9 throughout the period, the decreasing trend warrants monitoring to ensure continued short-term solvency.